Logo image of BBOT

BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BBOT - US1079241022 - Common Stock

13.69 USD
+2.15 (+18.63%)
Last: 12/5/2025, 8:04:22 PM
14 USD
+0.31 (+2.26%)
After Hours: 12/5/2025, 8:04:22 PM
Fundamental Rating

2

BBOT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. BBOT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BBOT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BBOT was profitable.
In the past year BBOT has reported a negative cash flow from operations.
BBOT Yearly Net Income VS EBIT VS OCF VS FCFBBOT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M 4M 6M

1.2 Ratios

BBOT has a Return On Assets of 2.39%. This is amongst the best in the industry. BBOT outperforms 89.35% of its industry peers.
BBOT has a Return On Equity of 2.49%. This is amongst the best in the industry. BBOT outperforms 90.47% of its industry peers.
Industry RankSector Rank
ROA 2.39%
ROE 2.49%
ROIC N/A
ROA(3y)-3.68%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBOT Yearly ROA, ROE, ROICBBOT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BBOT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBOT Yearly Profit, Operating, Gross MarginsBBOT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for BBOT has been increased compared to 1 year ago.
There is no outstanding debt for BBOT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BBOT Yearly Shares OutstandingBBOT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
BBOT Yearly Total Debt VS Total AssetsBBOT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

BBOT has an Altman-Z score of 80.50. This indicates that BBOT is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 80.50, BBOT belongs to the best of the industry, outperforming 98.69% of the companies in the same industry.
There is no outstanding debt for BBOT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 80.5
ROIC/WACCN/A
WACCN/A
BBOT Yearly LT Debt VS Equity VS FCFBBOT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 0.33 indicates that BBOT may have some problems paying its short term obligations.
The Current ratio of BBOT (0.33) is worse than 94.02% of its industry peers.
A Quick Ratio of 0.33 indicates that BBOT may have some problems paying its short term obligations.
With a Quick ratio value of 0.33, BBOT is not doing good in the industry: 93.83% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.33
BBOT Yearly Current Assets VS Current LiabilitesBBOT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.40% over the past year.
EPS 1Y (TTM)17.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -109.66% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1064.33%
EPS Next 2Y-194.11%
EPS Next 3Y-109.66%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BBOT Yearly EPS VS EstimatesBBOT Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 68.45, the valuation of BBOT can be described as expensive.
BBOT's Price/Earnings ratio is rather cheap when compared to the industry. BBOT is cheaper than 90.09% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.49. BBOT is valued rather expensively when compared to this.
BBOT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 68.45
Fwd PE N/A
BBOT Price Earnings VS Forward Price EarningsBBOT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBOT Per share dataBBOT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as BBOT's earnings are expected to decrease with -109.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-194.11%
EPS Next 3Y-109.66%

More info and screens

0

5. Dividend

5.1 Amount

BBOT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIDGEBIO ONCOLOGY THERAPEUT

NASDAQ:BBOT (12/5/2025, 8:04:22 PM)

After market: 14 +0.31 (+2.26%)

13.69

+2.15 (+18.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-03 2026-03-03
Inst Owners45.89%
Inst Owner ChangeN/A
Ins Owners0.11%
Ins Owner Change5.96%
Market Cap1.10B
Revenue(TTM)N/A
Net Income(TTM)4.72M
Analysts86.67
Price Target24.48 (78.82%)
Short Float %1.68%
Short Ratio5.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.83%
PT rev (3m)4.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.95%
EPS NY rev (1m)-57.62%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 68.45
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.79
P/tB 5.79
EV/EBITDA N/A
EPS(TTM)0.2
EY1.46%
EPS(NY)-2.38
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS2.37
TBVpS2.37
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.26
Profitability
Industry RankSector Rank
ROA 2.39%
ROE 2.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3.68%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.33
Altman-Z 80.5
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.45%
EPS Next Y-1064.33%
EPS Next 2Y-194.11%
EPS Next 3Y-109.66%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1399.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

BRIDGEBIO ONCOLOGY THERAPEUT / BBOT FAQ

What is the fundamental rating for BBOT stock?

ChartMill assigns a fundamental rating of 2 / 10 to BBOT.


Can you provide the valuation status for BRIDGEBIO ONCOLOGY THERAPEUT?

ChartMill assigns a valuation rating of 1 / 10 to BRIDGEBIO ONCOLOGY THERAPEUT (BBOT). This can be considered as Overvalued.


How profitable is BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?

BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) has a profitability rating of 2 / 10.


What is the financial health of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?

The financial health rating of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 5 / 10.


Can you provide the expected EPS growth for BBOT stock?

The Earnings per Share (EPS) of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is expected to decline by -1064.33% in the next year.